TY - JOUR T1 - Proteomic analysis of intermediate uveitis suggests myeloid cell recruitment and implicates IL-23 as a therapeutic target. JF - Am J Ophthalmol Case Rep Y1 - 2020 A1 - Sepah, Yasir J A1 - Velez, Gabriel A1 - Tang, Peter H A1 - Yang, Jing A1 - Chemudupati, Teja A1 - Li, Angela S A1 - Nguyen, Quan D A1 - Bassuk, Alexander G A1 - Mahajan, Vinit B AB -

Purpose: To profile vitreous protein expression of intermediate uveitis (IU) patients.

Observations: We identified a mean of 363 ± 41 unique proteins (mean ± SD) in IU vitreous and 393 ± 69 unique proteins in control samples using liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of liquid vitreous biopsies collected during pars plana vitrectomy. A total of 233 proteins were differentially expressed among control and IU samples, suggesting a protein signature that could distinguish the two groups. Pathway analysis identified 22 inflammatory mediators of the interleukin-12 (IL-12) signaling pathway in IU vitreous. Upstream regulator analysis identified downstream mediators of IL-23 and myeloid differentiation primary response protein (MYD88), both of which are involved in the recruitment and differentiation of myeloid cells. Taken together, our results suggest the recruitment of myeloid cells as an upstream pathway in the pathogenesis of IU.

Conclusions: This study provides insights into proteins that will serve as biomarkers and therapeutic targets for IU. These biomarkers will help design future clinical trials using rational molecular therapeutics.

VL - 18 ER -